Participants, methods, and results
We sent an anonymous questionnaire (see bmj.com) to all lead clinicians in English genitourinary medicine clinics in December 2003. We excluded centres which do not treat HIV infected patients. We contacted doctors who work at more than one site only once. The questionnaire asked about the doctor's experience of and opinion about the appropriateness of dispersal in 10 clinical scenarios and also about perceived barriers to effective dispersal (table) . For each centre we recorded its location and the number of patients dispersed.
Of 75 eligible centres, 56 returned questionnaires; 34 of these were outside London and a third (20) had had an HIV infected asylum seeker dispersed to them. A total of 13 centres had had patients dispersed both to and from them. Of those who did not respond, 15/19 were from outside London. Thirty six centres had no experience of dispersal.
Of the 56 returned questionnaires, often cited barriers to successful dispersal were dispersal at short notice (37) or with no prior arrangement (43). Only three centres had experienced appropriate transfer of care. Other barriers included lack of community support (41), lack of facilities to support vulnerable asylum seekers with psychological problems (43), and low staffing levels in the receiving centre (40).
Although the questionnaire did not ask for specific negative consequences attributable to dispersal, some doctors added spontaneous comments. These included problems relating to unintentional interruption to antiretroviral therapy (4), mother to child transmission of HIV infection (3), and HIV related death (2) . Of 33 centres reporting experience of patients being dispersed away from their service, 19 had experience of dispersal against medical advice.
Many of the 56 doctors felt that dispersal of HIV infected asylum seekers was inappropriate in specific situations-during initiation of antiretroviral therapy (47), in patients receiving salvage treatment (43), in those currently undergoing medical investigations (50), where care involved multiple medical specialties (52), and in those with AIDS (45).
Comment
We identified several potential barriers to the safe dispersal of HIV infected asylum seekers. Of particular concern is that dispersal is done at short notice and often without appropriate transfer of medical details. Although hand held medical records have been suggested as a potential solution, 4 they are unlikely to resolve all the issues that could compromise patient care. Inappropriate dispersal of an HIV infected patient could lead to HIV resistance, onward transmission of HIV infection, and avoidable morbidity and mortality for the asylum seeker. Before the decision to disperse, the National Asylum Support Service should seek specialist advice and consider the impact on the infrastructure and staffing of the receiving centre.
Responses to the statement "Dispersal of HIV positive persons of insecure immigration status is safe and appropriate in the following situations" from 56 lead doctors at English genitourinary clinics 
Acquired haemophilia A may be associated with clopidogrel
Montaser Haj, H Dasani, S Kundu, U Mohite, P W Collins Acquired haemophilia A is a rare bleeding disorder caused by autoantibodies against factor VIII. 1 Bleeding is often severe and may be life threatening. In half of patients, no underlying disorder is found, however, common associations are with autoimmune disease, malignancy, dermatological disorders, pregnancy, and drugs. [1] [2] [3] Two women aged 70 and 67 presented with a history of excessive bruising and soft tissue bleeding 2-3 months after starting clopidogrel (Plavix; Bristol-Myers Squibb, Sanofi-Synthelabo) for peripheral vascular disease. Their drugs had not changed recently in any other way. They had no clinical symptoms or signs of malignancy, antiphosphpolipid syndrome, or collagen vascular disease.
One patient had had a documented normal activated partial thromboplastin time at the time of starting clopidogrel; the other had not been tested. Investigation showed that the women had a normal platelet count, peripheral blood film, and prothrombin time. Both had a prolonged activated partial thromboplastin time of 48.6 and 77.6 seconds (normal range 23-33 seconds). Tests for lupus anticoagulant, anticardiolipin antibody, antinuclear factor, double stranded DNA, and rheumatoid factor were negative. The women had low factor VIII (3.9 and 1 IU/dl) with normal von Willebrand factor levels and a detectable antifactor VIII inhibitor (2.2 and 17.6 Bethesda units). We treated both patients with 1 mg/kg of prednisolone. Concentrations of factor VIII rose to 119 and 136 IU/dl, and the inhibitor became undetectable ( < 0.4 Bethesda units) within eight weeks of treatment. The factor VIII inhibitor relapsed in one patient when the steroid dose was reduced, but we induced and sustained remission with azathioprine.
A possible link between autoimmune acquired haemophilia and clopidogrel has not been previously reported. Clopidogrel has been associated with microangiopathic haemolytic anaemia and thrombocytopenia, 4 5 suggesting other possible immune mediated adverse events.
Increased bruising should not be ascribed to the antiplatelet action of clopidogrel unless a platelet count and coagulation screen have been found to be normal. Investigation for an antifactor VIII inhibitor should be done if indicated by a prolonged activated partial thromboplastin time.
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